Last reviewed · How we verify
Furadantin (NITROFURANTOIN)
Nitrofurantoin is an antibacterial drug.
At a glance
| Generic name | NITROFURANTOIN |
|---|---|
| Sponsor | Casper Pharma Llc |
| Drug class | Nitrofuran Antibacterial [EPC] |
| Target | CDGSH iron-sulfur domain-containing protein 1 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1953 |
Mechanism of action
Mechanism of Action. The mechanism of the antimicrobial action of nitrofurantoin is unusual among antibacterials.Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates which inactivate or alter bacterial ribosomal proteins and other acromolecules. As result of such inactivations, the vital biochemical processes of protein synthesis, aerobic energy metabolism, DNA synthesis, RNA synthesis, and cell wall synthesis are inhibited. Nitrofurantoin is bactericidal in urine at therapeutic doses. The broad-based nature of this mode of action may explain the lack of acquired bacterial resistance to nitrofurantoin, as the necessary multiple and simultaneous mutations of the target macromolecules would likely be lethal to the bacteria.Interactions with Other AntibioticsAntagonism has been demonstrated in vitro between nitrofurantoin and quinolone antimicrobials. The clinical significance of this finding is unknown.Development of ResistanceDevelopment of resistance to nitrof
Approved indications
- Enterobacter Cystitis
- Enterococcus Urinary Tract Infection
- Escherichia coli urinary tract infection
- Klebsiella cystitis
- Staphylococcus Aureus Urinary Tract Infection
- Staphylococcus Saprophyticus Urinary Tract Infection
Common side effects
- Chronic pulmonary reactions
- Subacute pulmonary reactions
- Peripheral neuropathy
- Hepatic reactions
- Hepatitis
- Cholestatic jaundice
- Hepatic necrosis
- Pseudomembranous colitis
- Aplastic anemia
- Cyanosis
- Nausea
- Emesis
Key clinical trials
- Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections (PHASE1)
- A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection (PHASE2)
- Role of Prophylactic Postoperative Antibiotics in HoLEP (PHASE4)
- Pediatric Pilonidal Sinus Surgical Treatment (NA)
- Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries (PHASE3)
- Intravesical Gentamicin to Prevent Recurrent UTI (PHASE4)
- Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections (PHASE1)
- NextGen - Clinical Implication of Next Generation Sequencing (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Furadantin CI brief — competitive landscape report
- Furadantin updates RSS · CI watch RSS